Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Atara Biotherapeutics (Nasdaq: ATRA), a company specializing in T-cell immunotherapy and developing treatments for cancer and autoimmune diseases using its allogeneic Epstein-Barr virus (EBV) T-cell platform, has scheduled the release of its third quarter 2024 financial results. The results will be announced after market close on Tuesday, November 12, 2024.
Atara Biotherapeutics (Nasdaq: ATRA), un'azienda specializzata in immunoterapia con cellule T e nello sviluppo di trattamenti per il cancro e le malattie autoimmuni utilizzando la sua piattaforma allogenica di cellule T del virus di Epstein-Barr (EBV), ha programmato la pubblicazione dei suoi risultati finanziari del terzo trimestre 2024. I risultati saranno annunciati dopo la chiusura del mercato di martedì 12 novembre 2024.
Atara Biotherapeutics (Nasdaq: ATRA), una compañía especializada en la inmunoterapia con células T y en el desarrollo de tratamientos para el cáncer y enfermedades autoinmunes utilizando su plataforma alogénica de células T del virus de Epstein-Barr (EBV), ha programado la publicación de sus resultados financieros del tercer trimestre de 2024. Los resultados se anunciarán después del cierre del mercado el martes 12 de noviembre de 2024.
Atara Biotherapeutics (Nasdaq: ATRA)는 T세포 면역 요법에 특화된 회사로, 이식용 Epstein-Barr 바이러스(EBV) T세포 플랫폼을 이용한 암 및 자가면역 질환 치료제를 개발하고 있으며, 2024년 3분기 재무 결과 발표 일정을 확정했습니다. 결과는 2024년 11월 12일 화요일 시장 종료 후에 발표될 예정입니다.
Atara Biotherapeutics (Nasdaq: ATRA), une entreprise spécialisée dans l'immunothérapie par cellules T et le développement de traitements pour le cancer et les maladies auto-immunes en utilisant sa plateforme de cellules T allogéniques du virus d'Epstein-Barr (EBV), a programmé la publication de ses résultats financiers du troisième trimestre 2024. Les résultats seront annoncés après la clôture du marché le mardi 12 novembre 2024.
Atara Biotherapeutics (Nasdaq: ATRA), ein Unternehmen, das auf T-Zell-Immuntherapie spezialisiert ist und Behandlungen für Krebs und Autoimmunerkrankungen mit seiner allogenen Epstein-Barr-Virus (EBV) T-Zell-Plattform entwickelt, hat die Veröffentlichung seiner Finanzergebnisse des dritten Quartals 2024 terminiert. Die Ergebnisse werden nach Handelsende am Dienstag, den 12. November 2024 bekannt gegeben.
- None.
- None.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105648474/en/
Investor and Media Relations:
Jason Awe, Ph.D.
Head of Corporate Communications & Investor Relations
(805) 217-2287
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
FAQ
When will Atara Biotherapeutics (ATRA) release Q3 2024 earnings?
What is Atara Biotherapeutics' (ATRA) main technology platform?
